Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-0610 in Malignant Peripheral Nerve Sheath Tumors
NCT02986919Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pelabresib in malignant peripheral nerve sheath tumor (MPNST), sponsored by UT Southwestern Medical Center. Primary endpoints: Response rate of CPI-0610 at 84 days, Duration of CPI-0610 at 84 days and 1 more. Planned start May 2017; status: withdrawn.
02
Drugs
pelabresib
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT02986919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986919.